Quantcast

Latest Factor VIII Stories

2009-02-12 07:30:00

IB1001, an Intravenous Recombinant Factor IX (rFIX) Product for the Treatment of Hemophilia B LAGUNA NIGUEL, Calif., Feb. 12 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., today announced the initiation of a Phase 1 clinical trial of IB1001, an intravenous (IV) recombinant Factor IX (rFIX) product for control and prevention of hemorrhagic episodes in patients with hemophilia B. It is estimated that the market for therapies to treat this disorder is in excess of $600 million. The...

2009-02-04 09:17:00

GAITHERSBURG, Md. and ATLANTA, Feb 4 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, and Expression Therapeutics, a biotechnology company specializing in factor VIII-based therapeutics, today announced a collaborative agreement to co-develop novel cell and protein therapies for Hemophilia A. Hemophilia A is an inherited blood clotting disorder caused by a mutation in the factor VIII gene...

2008-12-22 11:30:10

Study holds hope for next generation hemophilia treatment Researchers have made several, subtle changes in the structure of a key protein, dramatically increasing its ability to drive blood clotting, according to a study published in a December edition of the Journal of Thrombosis and Haemostasis. The findings have profound implications for the treatment of hemophilia, the inherited blood disorder that causes easy or excessive bleeding in 30,000 Americans. In most cases, hemophilia is caused...

2008-11-13 15:00:29

MILWAUKEE, Nov. 13 /PRNewswire/ -- Investigators at Children's Research Institute, BloodCenter of Wisconsin's Blood Research Institute and the Medical College of Wisconsin have discovered a new way to help the blood clot by having the missing clotting factor packaged in the patient's own platelets. In the October 2008 edition of Blood, investigators describe how a gene-modified bone marrow transplant can be used to initiate clotting in hemophilia. This type of approach may work in the 30 to...

2008-11-13 09:00:36

BEIJING, Nov. 13 /PRNewswire/ -- Bayer Schering Pharmaceuticals, the leading pharmaceutical company in China and a global leader in hemophilia care, announced today a euro 1.5 million pledge to develop Hemophilia Treatment Centers (HTCs) throughout China. Over the next five years, Bayer's support will fund a variety of necessities, including equipment and supplies, patient programs, educational materials, medical training and nursing support. The Bayer China Hemophilia Treatment Center...

2008-11-12 12:00:31

NEW YORK, Nov. 12 /PRNewswire/ -- Val Bias, Chief Executive Officer of the National Hemophilia Foundation is featured in the November 2008 issue of Black Enterprise magazine in the "On the Move" section of the Powerplay Department. The department highlights African-American men and women who have been appointed to new management positions in the upper echelons of the corporate world. Recent announcements have included leadership posts at BET, MTV and Northrop Grumman. Black Enterprise...

2008-11-12 03:00:16

STOCKHOLM, Sweden and MADISON, New Jersey, USA - November 12, 2008. Biovitrum AB (publ) (STO: BVT) and Wyeth (NYSE: WYE) today announced an extension of the ReFacto(R) supply agreement until December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto(R), as well as Xyntha(R)/ReFacto(R) AF, the successor products, and will continue to receive royalties from Wyeth's global sales. Biovitrum's co-promotion rights in the Nordic region...

2008-10-27 12:00:29

The European Medicines Agency (EMEA) has granted license approval to Bayer HealthCare LLC (Bayer) for its new sterile filling facility (SFF) on its Berkeley, Calif. campus. The approval closely follows authorization already given by the U.S. Food and Drug Administration in August 2008. Together, these licenses from the regulatory bodies ensure this state-of-the-art facility is ready to support the supply of Bayer's Kogenate(R) FS/ KOGENATE(R) Bayer (Antihemophilic Factor (Recombinant)) line...

2008-10-13 12:00:41

The U.S. Food and Drug Administration has approved a new use for the blood product Kogenate FS in children with the most severe form of hemophilia. The FDA said Kogenate FS is meant to reduce the frequency of bleeding episodes and prevent joint damage in such children. Hemophilia A is a rare, hereditary, bleeding disorder in which a protein needed to form blood clots, factor VIII, is missing or its level is reduced. The FDA said the disorder affects about 15,000 individuals in the United...

2008-10-10 12:00:42

BERKELEY, Calif., Oct. 10 /PRNewswire/ -- Bayer HealthCare LLC announced today that the U.S. Food and Drug Administration (FDA) has approved routine prophylaxis with Kogenate(R) FS Antihemophilic Factor (Recombinant) to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage. This important approval provides these patients with the only factor VIII treatment that the FDA has determined safe...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'